

# MARKET REPORT



Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021)

**BioPortfolio**

Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021)

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021)

Depression is a mood disorder that causes relentless feeling of sadness. Many factors causes depression, including brain biology and chemistry, genetics and life events such as trauma, complicated relationships, childhood experiences, loss of a loved one and any stressful situation.

The symptoms of depression are often treated by several types of medications, also known as antidepressant drugs. The most common antidepressant drugs used to treat depression are Celexa, Zoloft, Cymbalta, Prozac, Paxil, Lexapro and Pristiq.

The global depression drugs market is growing due to rising awareness about different types of depression and their treatment. In addition, rising geriatric population, growing numbers of patients suffering from depression in developed countries such as U.S. and Canada, are also supporting to the growth of the market. However, stringent regulations for the approval of antidepressants, patent expiry of several blockbuster antidepressants drugs and strict regulations for the commercial usage of antidepressants without prescription are some of the major restraints hamper the growth of the global depression drugs market.

The global depression drugs market is segmented based on various depression medication classes, brand and geography. Based on the depression medication classes, the market is sub-segmented into monoamine oxidase inhibitors (MAOIs), serotonin-norepinephrine reuptake inhibitors (SNRI), anticonvulsants, beta-blockers, tetracyclic antidepressants (TeCAs), benzodiazepines, selective serotonin reuptake inhibitors (SSRIs) and others. Amongst the medication classes, SNRI is the highest revenue segment in the current scenario.

On the basis of brand, the global depression drugs market is bifurcated into Celexa, Zoloft, Cymbalta, Prozac, Paxil, Lexapro, Pristiq and others. From the geographical perspectives, the market is segmented in North America (USA, Mexico and Canada), Europe (U.K., Germany, France, Spain, Italy and Rest of Europe), Asia Pacific (Japan, India, China, Australia and Rest of Asia Pacific) and Rest of the World (Middle East, Latin America and Africa). North America, followed by Europe, holds major market share in the global depression drugs market due to presence of large population base suffering from various types of depression. Asia Pacific is expected to grow at a moderate growth rate during the forecast period due to increasing investment by several drug manufacturing companies owing to low wages, minimal investment, large population base and availability of skilled labour.

The dominant players in the Depression Drugs Market are:

Novartis International AG

Abbott Laboratories

<https://www.bioportfolio.co.uk/product/80272-reportstore@bioportfolio.com> to order

Allergan, Plc

Janssen Pharmaceuticals, Inc.

Lupin Pharmaceuticals, Inc.

## Additional Details

**Publisher** : Industry ARC

**Reference** : HCR 0242

**Number of Pages** : 0

**Report Format** : PDF

**Publisher Information** :



IndustryARC is the Leading Provider of Market Research Reports, Custom Consulting Services, Data Analytics and Industry Analysis. Our goal is to provide the right information required by the stakeholder at the right point of time, in a format which assists an intelligent and informed decision making process!

We provide profound information with a proactive collaboration with the clients to identify new opportunities and guide them to find the best strategy for finding growth avenues. Our in-depth Research Reports with analysis done by experienced consultants and inputs from industry experts, Key Opinion Leaders (KOLs) span multiple sectors such as:

# Table Of Contents for Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021) [Report Updated: 25-02-2016]

- 1. Depression Drugs Market Overview2. Executive Summary3. Depression Drugs - Market Landscape3.1. Market Share Analysis3.2. Comparative Analysis3.2.1. Product Benchmarking3.2.2. End user profiling3.2.3. Patent Analysis3.2.4. Top 5 Financials Analysis4. Depression Drugs - Market Forces4.1. Market Drivers4.1.1. Rising Awareness about Different Types of Depression4.1.2. Rising Geriatric Population 4.1.3. Increasing Incidences of Depression 4.2. Market Constraints4.2.1. Stringent Regulations for the Approval of Antidepressants4.2.2. Strict Regulations for the Commercial Usage of Antidepressants without prescription4.2.3. Patent Expiry of Several Blockbuster Antidepressant Drugs4.3. Market Challenges4.3.1. Narrow Drug Pipelines4.4. Attractiveness of the Industry4.4.1. Power of Suppliers4.4.2. Power of Customers4.4.3. Threat of New entrants4.4.4. Threat of Substitution4.4.5. Degree of Competition5. Depression Drugs Market- Strategic Analysis5.1. Value Chain Analysis5.2. Pricing Analysis5.3. Opportunities Analysis6. Depression Drugs Market - By Medication Class6.1. Monoamine Oxidase Inhibitors (MAOIs)6.2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRI)6.3. Anticonvulsants6.4. Beta-Blockers6.5. Tetracyclic Antidepressants (TeCAs)6.6. Benzodiazepines6.7. Selective Serotonin Reuptake Inhibitors (SSRIs) 7. Depression Drugs Market - By Brand7.1. Celexa7.2. Zoloft7.3. Cymbalta7.4. Prozac7.5. Paxil7.6. Lexapro7.7. Prestiq7.8. Others8. Depression Drugs Market - Geographical Analysis8.1. Introduction 8.2. North America8.2.1. USA8.2.2. Mexico8.2.3. Canada8.3. Europe8.3.1. Germany8.3.2. France8.3.3. U.K.8.3.4. Italy8.3.5. Spain8.3.6. Rest of Europe8.4. APAC8.4.1. China 8.4.2. India8.4.3. Japan8.4.4. Australia8.4.5. Rest of APAC8.5. Rest of the World (RoW)9. Market Entropy9.1. New Product Launches9.2. Mergers and Acquisitions,9.3. Collaborations, JVs and Partnerships10. Company Profiles (Overview, Financials, SWOT Analysis - Top 05 Companies, Developments and Product Portfolio)10.1. Novartis International AG10.2. Janssen Pharmaceuticals, Inc.10.3. Lupin Pharmaceuticals, Inc.10.4. Abbott Laboratories10.5. Allergan, Plc10.6. MSI Methylation Sciences Inc.10.7. Luye Pharma Group Ltd.10.8. H. Lundbeck A/S\*More than 40 Companies are profiled in this Research Report, Complete List available on Request\*\*Financials would be provided on a best efforts basis for private companies"11. Appendix11.1. Abbreviations11.2. Sources11.3. Research Methodology11.4. Bibliography11.5. Compilation of Expert Insights11.6. Disclaimer

List Of Tables in Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021) [Report Updated: 25-02-2016]

No

# How to Buy...

Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021) [Report Updated: 25-02-2016]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/80272>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$5250** | Single User Price
- \$6250** | Site License Price
- \$8450** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.